胸腺肽a1联合化疗治疗肺结核合并糖尿病疗效观察  

Clinical Study of Thymosin α1 in Combination with Chemotherapy in treatment of TB Accompanied with Diabetes

作　　者：那琳琳[1] 张莉[1] 王莹[1] 齐正波[1] 

机构地区：[1]哈尔滨二四二医院,黑龙江哈尔滨150060

出　　处：《哈尔滨医药》2012年第1期9-9,共1页Harbin Medical Journal

摘　　要：目的观察胸腺肽α1辅助治疗肺结核合并糖尿病患者的临床疗效。方法将56例肺结核合并糖尿病患者随机分成2组,观察组和对照组。在常规抗结核治疗和降糖治疗基础上,观察组加用胸腺肽a1(迈普新1.6 mg 1周2次皮下注射)。结果治疗6个月后观察组在病灶吸收,痰菌转阴,空洞缩小及闭合等方面,均优于对照组。结论胸腺肽a1作为抗结核的辅助治疗可明显提高肺结核合并糖尿病患者的临床疗效。Objective To investigate the effect of thymosin α1 in the adjutant treatment of tuberculosis（TB） accompanied with diabetes.Methods The 56 patients with TB accompanied with diabetes were randomly divided into two groups,treatment and control groups.The treatment group received 1.6 mg thymosinα1（maipuxin） subcutaneous injections twice weekly,whereas the control one did not.Results In comparation with the contrast group,the remission of pulmonary lesion,sputum negative conversion,and reduction and closure of cavities were improved significantly in the treatment group after.treatment for 6 months.Conclusion Thymosin α1 may be conducive to treat TB,can highly improve the therapeutic effect on patients with TB accompanied with diabetes.

关 键 词：肺结核 抗结核药物 胸腺肽A1 

分 类 号：R521[医药卫生—内科学]